This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Butchart, E. G. Search for Related Content PubMed PubMed Citation Articles by Butchart, E. G.

Contemporary Management of Malignant Pleural Mesothelioma

University Hospital of Wales, Cardiff, United Kingdom

Correspondence: Eric G. Butchart, M.D., Consultant Cardiothoracic Surgeon, University Hospital, Cardiff, CF4 4XW, Wales, UK. Telephone: 44-1222-743284; Fax: 44-1446-781316; e-mail: egbutchart{at}aol.com

The rapidly increasing incidence of malignant pleural mesothelioma underlines the urgency to achieve a consensus in the management of this tumor, which is biologically distinct from most other tumors. For patients with stage I tumors of epithelial type and good performance status, pleuropneumonectomy combined with chemotherapy and radiotherapy provides the best chance of prolonged survival, but further investigation is required to determine the optimum combination of adjuvant therapy. Debulking pleurectomy/decortication combined with adjuvant therapy is a worthwhile alternative for patients with more advanced disease, impaired performance status or tumors of less favorable histology (sarcomatous or biphasic). More clinical trials are urgently required to identify better adjuvant therapy for tumors containing sarcomatous elements. On currently available evidence, neither radiotherapy nor chemotherapy offer worthwhile prolonged disease control when used in isolation, although both have an important role as part of multimodality therapy. Hyperthermia may enhance the effect of both radiotherapy and chemotherapy, and newer radiosensitizing agents also need evaluating. Research into immunotherapy and gene therapy suggests that these newer approaches may have a place if tumor volume is small. In practice they will probably need to be combined with other therapeutic modalities, and further clinical trials are required. Consensus in mesothelioma management currently remains elusive but it seems clear that the way forward will involve striving for much earlier diagnosis, the use of multimodality therapy and collaboration between centers with special expertise in mesothelioma treatment to organize multicenter trials.

Key Words. Mesothelioma • Surgery • Radiotherapy • Chemotherapy • Immunology • Gene therapy

This article has been cited by other articles:

				T. Treasure, D. Waller, S. Swift, and J. Peto Radical surgery for mesothelioma BMJ, January 31, 2004; 328(7434): 237 - 238. [Full Text] [PDF]

				K. Uematsu, S. Kanazawa, L. You, B. He, Z. Xu, K. Li, B. M. Peterlin, F. McCormick, and D. M. Jablons Wnt Pathway Activation in Mesothelioma: Evidence of Dishevelled Overexpression and Transcriptional Activity of {beta}-Catenin Cancer Res., August 1, 2003; 63(15): 4547 - 4551. [Abstract] [Full Text] [PDF]